What affects anticoagulation control in patients taking warfarin?
Lindsay Smith, Edzard Ernst, Paul Ewings, Jeffrey Allen, Caroline Smith and Catherine Quinlan

ABSTRACT
Background
The ageing population is taking an increasing number of both prescribed and non-prescribed medication. Little is known of the potential for adverse drug reactions between these. Warfarin is a commonly prescribed medication, well known for its potential to cause serious adverse reactions in combination with many prescription medicines. It has been suggested that herbal medicines such as garlic, either as a dietary supplement or in cooking, may also interact with warfarin, resulting in poor international normalised ratio (INR) control.

Aim
To determine whether, for patients who take garlic as well as warfarin, the proportion of the INR tests in range is lower than in comparable patients who do not take garlic.

Design of the study
Retrospective study of patients taking prescribed warfarin.

Setting
Primary care practices in Somerset and Devon.

Method
Three controls (not taking garlic) matched for age, sex, and general practice were compared with each patient self-reporting taking garlic as a supplement. INR results were assessed for the preceding 12 months. Potentially confounding factors were considered, for example diabetes mellitus; all prescribed medication; any bleeding episodes.

Results
No evidence was found to suggest that garlic consumption either as a supplement or in cooking is associated with more frequent haemorrhagic complications or less control of INR. Poor INR control may, however, be associated with taking larger numbers of prescription medicines, particularly during prescription changes.

Conclusion
Further research would be warranted into whether increased INR monitoring is needed when drug changes are made. These data render clinically significant interactions between warfarin and garlic intake unlikely.

Keywords
anticoagulation; complementary medicine; garlic; prescriptions; warfarin.

INTRODUCTION
The ageing population is taking an increasing number of medications of all types: prescription,1 over-the-counter (OTC),2 complementary, and alternative.3–5 Warfarin is a commonly prescribed medication which is well known for its potential to cause serious adverse drug reactions, namely bleeding,6,7–9 especially as a result of many prescription medications interacting with it. In addition, some herbal preparations may interact with it as well. However, there is a widely-held public belief that, because many of the non-prescription medications are ‘natural’ remedies, they can do no harm.10 Unfortunately, many can cause adverse effects,11 just as traditional prescription medication can.9 Of particular concern is the possibility of such herbal preparations interacting with prescription medicines;12 increasing the risk of an adverse reaction or altering the pharmacodynamics of the prescribed drug.

One common herbal preparation is garlic. Patients usually take it for the prevention of cardiovascular disease, and a recent review concluded that it is superior to placebo in reducing total cholesterol levels, even though the size of the effect is of debatable clinical relevance.13 Garlic is also cited as potentiating the effect of warfarin, and affecting the

L Smith, MCLinSci, MD, FRCP, FRCPG; research lead; C Smith, RGN, RM, research associate; C Quinlan, BSc(Hons), DipM, research administrator, East Somerset Research Consortium, West Coker. E Ernst, MD, PhD, FRCP, FRCPEd, professor of complementary medicine, Peninsula Medical School, Universities of Exeter and Plymouth, Exeter. P Ewings, BSc, MSc, PhD, CStat, director, Research Design Service, National Institute for Health Research, Taunton. J Allen, BSc(Hons), PhD, DipRCPath, research manager, Taunton and Somerset Re&D Consortium, Taunton and Somerset NHS Foundation Trust, Taunton.

Address for correspondence
Dr Lindsay FP Smith, East Somerset Research Consortium, Westlake Surgery, West Coker, Somerset BA22 9AH.
E-mail: research@esrec.nhs.uk


©British Journal of General Practice

This article was originally online first on 15 July 2009. Cite this article as: Br J Gen Pract 2009; 59: 590–594.
international normalised ratio (INR), although the evidence presented in review articles appears to be limited to anecdote and occasional case reports. It is uncertain whether increased bleeding times, if a real effect, are due to reduced platelet function, or prolonged prothrombin or partial thromboplastin times.

When undertaking a prevalence study in the south west of England, the authors found that in a population of 1360 patients on long-term warfarin, approximately 100 (7%) were taking garlic as well as warfarin. The study did not investigate the control of INR in relation to garlic ingestion, and therefore this retrospective study was conducted to test whether INR control is jeopardised if patients take garlic and/or other prescription medicines.

The present study aimed to answer the question: for patients who take garlic as a dietary supplement as well as warfarin, is the proportion of their INR tests in range lower than in comparable patients who do not take garlic? Secondary objectives were: to assess the effects of prescription medicines and garlic (as a supplement or in cooking) on INR control, and the number of major bleeding episodes and disease complications.

**METHOD**

In the autumn of 2005, all general medical practices in Somerset and Devon that participated in the original WHIST (Warfarin Herb Interaction Study) study were invited by letter to take part in this second study. Each participating practice was paid between £50 and £200, depending on list size, to cover their administrative costs. Approvals were obtained from both the Somerset and Devon Ethics Committees and primary care trusts. It is standard practice in these two counties for patients on warfarin to be monitored solely by their GP, who receives INR results and then advises the patient on any dose changes that may be required and the time interval until their next INR test. A few practices test the INR within the practice (near-patient testing), and a small minority of patients are managed by secondary care.

Those practices that agreed to take part searched their electronic patient databases to identify all patients who were taking warfarin, and sent them an invitation letter, information sheet, consent form, freepost envelope, and questionnaire. This questionnaire was based on that used in the previous study (available on request). Two weeks later, a short reminder was sent by practices to all patients who were sent the original mailing. Replies were returned to the central research office. Practices were excluded if they did not use electronic patient records. Patients were excluded if they had been taking warfarin for less than 3 months, were terminally ill, <18 years of age, unable to read English, or unable to understand the consent form (for example, those with dementia). Participating practices were responsible for excluding these patients from their mailing lists.

Three controls (not taking garlic) were compared with each patient self-reporting taking garlic as a supplement. The returned questionnaires were used to identify those patients taking garlic supplements. For each such patient, the three controls that most closely matched were selected from those patients on warfarin who had reported not taking garlic. Controls were matched on age (within 3 years), sex, and general practice. The signed consent form gave permission for the researchers to review patients’ primary care medical records. Two research assistants visited participating practices and searched the patients’ GP electronic records for the 12 months prior to the consent date, without being aware of which patients had been taking garlic: a standard proforma was used for extraction. All INR results with dates were noted, as well as a number of potentially confounding diagnoses, for example diabetes mellitus, all prescribed medication, and any bleeding episodes. Patient questionnaires were relied upon to record herbal intake of garlic and frequency of use in cooking.

The primary outcome measure was the proportion of INR tests in the target range within the 12-month period prior to the signed consent date; it was assumed that the index INR applied to the whole time period back to the previous INR result. Secondary outcome measures were: the percentage of time INR was within the target range, average number of INR tests undertaken in previous year, and incidence of bleeding side-effects.

Based on a systematic review, it was expected that approximately 60% of INR test results would be within the target range. To detect a 10% change in this figure with a power of 80% and \( P = 0.05 \), the study would need 75 patients taking garlic and 225 controls. With the planned size as above it would have been possible to detect a change of 20% in adverse effects.

Useable replies were entered onto a database and SPSS was used for analysis. Descriptive data are presented summarising the outcome measures within the two groups of patients. Planned independent
variables included reason for taking warfarin, duration of warfarin treatment, presence or absence of co-ingestion of garlic in cooking, age, co-ingestion or not of other medication known to affect INR and/or blood clotting, and diabetes mellitus. Associations were tested using either Student’s \( t \)-test, Pearson’s \( \chi^2 \), Mann–Whitney \( U \) test, or Spearman’s \( \rho \). Prescribed medication was classified as potentiating (definitely or possibly), no effect, or inhibiting (possibly or definitely) the effect of warfarin on the INR according to the British National Formulary.26

**RESULTS**

Of 87 practices invited, 21 took part. These practices identified 1790 eligible patients, of whom 1130 (63%) returned consent forms and questionnaires. Fifty-four patients reported taking garlic as a dietary supplement: 39 took it daily, nine most days, and five weekly (one not known); they had taken it for variable durations (<1 year, \( n = 7 \); 1–4 years, \( n = 14 \); 5–9 years, \( n = 21 \); ≥10 years, \( n = 2 \)). Of 205 patients, 39 never used garlic in cooking, 99 used it occasionally, 41 weekly, 20 on most days, and six used it daily (11 not known). Those taking garlic supplements were more likely to use garlic regularly in cooking (\( P < 0.001 \)) and to take other supplements (\( P < 0.001 \); Table 1). No significant differences were found for other important variables (Table 1).

Patients were taking a wide range of prescribed medication. It was noted for each of these whether the patient had taken it continuously for the 12 months prior to consent, taken it intermittently, for example an antibiotic, stopped it having taken it as a regular repeat, or started it as a regular repeat, for example a blood pressure-lowering tablet (Table 2).

Thirty-two patients suffered abnormal bleeding (28 rectal bleeding, three subconjuntival haemorrhage, and one extensive skin bruising); the incidence of abnormal bleeding was similar between the two groups (9.3% of the 54 taking garlic supplements)

<table>
<thead>
<tr>
<th>Table 1. Characteristics of those 216 patients taking or not taking garlic as a dietary supplement.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
</tr>
<tr>
<td>Age, <em>y</em> years; mean (SD)</td>
</tr>
<tr>
<td>Male sex</td>
</tr>
<tr>
<td>Any other supplement</td>
</tr>
<tr>
<td>Any OTC medication</td>
</tr>
<tr>
<td>Diabetes</td>
</tr>
<tr>
<td>Reason for taking warfarin:</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>Previous stroke</td>
</tr>
<tr>
<td>Previous DVT or embolus</td>
</tr>
<tr>
<td>Heart valve replacement</td>
</tr>
<tr>
<td>Heart failure</td>
</tr>
<tr>
<td>Duration of use, years; median (IQR)*</td>
</tr>
</tbody>
</table>

**RESULTS**

Of 87 practices invited, 21 took part. These practices identified 1790 eligible patients, of whom 1130 (63%) returned consent forms and questionnaires. Fifty-four patients reported taking garlic as a dietary supplement: 39 took it daily, nine most days, and five weekly (one not known); they had taken it for variable durations (<1 year, \( n = 7 \); 1–4 years, \( n = 14 \); 5–9 years, \( n = 21 \); ≥10 years, \( n = 2 \)). Of 205 patients, 39 never used garlic in cooking, 99 used it occasionally, 41 weekly, 20 on most days, and six used it daily (11 not known). Those taking garlic supplements were more likely to use garlic regularly in cooking (\( P < 0.001 \)) and to take other supplements (\( P < 0.001 \); Table 1). No significant differences were found for other important variables (Table 1).

Patients were taking a wide range of prescribed medication. It was noted for each of these whether the patient had taken it continuously for the 12 months prior to consent, taken it intermittently, for example an antibiotic, stopped it having taken it as a regular repeat, or started it as a regular repeat, for example a blood pressure-lowering tablet (Table 2).

Thirty-two patients suffered abnormal bleeding (28 rectal bleeding, three subconjuntival haemorrhage, and one extensive skin bruising); the incidence of abnormal bleeding was similar between the two groups (9.3% of the 54 taking garlic supplements)
Medication was not significantly associated with INR range (ρ = 0.02; higher or lower than the target range (Table 1). Garlic supplementation was not significantly associated with the median percentage of tests either (Mann–Whitney U test, P = 0.24). Excluding those patients not taking warfarin and/or those not taking garlic for at least 1 year did not affect these results (P = 0.27). Garlic supplementation was not significantly associated with the median percentage of tests either higher or lower than the target range (Table 1). Garlic in cooking was not significantly correlated with the percentage of tests above, below, or within the target INR range (p = 0.11, P = 0.12; p = 0.08, P = 0.29; p = –0.02; P = 0.75 respectively). The taking of any OTC medication was not significantly associated with INR control (results not shown).

Use of garlic and OTC medication and INR control
Taking garlic as a dietary supplement was not associated with deterioration of INR control. The median (interquartile range [IQR]) number of days in the previous 12 months when the INR results were low, in the target range, or high were 27 (3–70), 285 (210–323) and 20 (3–46) respectively. The median (IQR) number of occasions when the INR results were low, in the target range, or high were 2 (1–5), 9 (7–11), and 2 (1–3) respectively.

Thirteen patients suffered thrombotic episodes (10 deep vein thrombosis, one pulmonary embolus, one transient ischaemic attack, and one stroke). These events were not associated with either taking garlic supplements (5.6% of 54 versus 6.2% of 162; Fisher's exact test P = 1.00) or garlic in food (Mann–Whitney U test, P = 0.73).

Prescription medication and INR control
Many patients were given drugs that are known to interact with warfarin (Table 2). The percentage of INR test results in the normal range was negatively associated with the number of new drugs started within the year (p = –0.15, P = 0.042), but not associated with the number of repeat drugs stopped during the year (p = –0.02, P = 0.82), the number of drugs used intermittently (p = –0.03, P = 0.74), or the number taken continuously (p = 0.12, P = 0.10). However, the percentage of test results below the target INR range was significantly associated with the number of drugs taken continuously (p = –0.17, P = 0.041) and the number of new repeat drugs started (p = 0.29, P<0.001). No significant associations were found with the number of INR results above the target range (all P values >0.20).

Medical conditions and INR control
The percentage of INR tests in the target range was significantly associated with patients having a heart valve replacement (Mann–Whitney U test, P = 0.006; median [IQR] = 48.7% [32.0–75.3%] with heart valve replacement versus 67.4% (56.0–80.0%) without heart valve replacement) but not with patients experiencing atrial fibrillation, heart failure, prior cerebrovascular accident, prior thrombosis, or ongoing diabetes mellitus (results not shown). However, the percentage number of tests below the target range was associated with heart valve replacement (P = 0.039; (18.5% (3.4–28.6%) heart valve replacement versus 6.2% (0–17.6%) no heart valve replacement), heart failure (P = 0.025; 1.1% [0–8.1%] with heart failure versus 8.8% [1.9–20.9%]), and with atrial fibrillation (P = 0.027; 12.0% (0–25.0%) with atrial fibrillation versus 20.0% (7.7–28.8%) without atrial fibrillation).

DISCUSSION
Summary of main findings and limitations of the study
No evidence was found to suggest that garlic consumed either as a supplement or as a foodstuff is associated with more frequent haemorrhagic complications or less control of INR. However, it was found that many patients on warfarin are being prescribed medication by their GP, that can affect INR control. In particular, poor INR control appears to be associated with taking larger numbers of prescription medicines, particularly during prescription changes. These findings are consistent with several scenarios. First, garlic might not interact with warfarin in a clinically relevant fashion. This is not an unlikely possibility as the documentation of such an interaction is based on less than convincing data. Second, the present study might have failed to detect a true interaction. Obviously observational data are plagued by a host of confounders, and also the size of this study might have been too small to detect a true difference in those taking garlic.

Comparison with existing literature
It is known that poor INR control is associated with antibiotic prescription and newly prescribed potentiating medication. The present study found that around a quarter of patients experienced such prescription medication changes during the study year. Such changes may well affect INR control and lead to either bleeding complications or complications of the disease for which the warfarin is prescribed. The study finding that poor INR control is associated with larger numbers of prescription medicines is consistent with published studies. However, it was found that INR results were more likely to be below the target INR range, reducing the chance of bleeding complications;
this may be because GPs were advising patients to reduce their warfarin dose because they were aware of the potential for interaction. Clearly, however, lowering of the INR would put patients at higher risk of complications of their disease process, for example thrombosis.

The ageing population is taking increasing numbers of drugs. This could lead to compliance problems. In the absence of certainty, it can be argued that patients and their professional carers should be cautious about the possibility of interactions between herbal or prescription medicines and warfarin. Patients only rarely discuss their non-prescription medicines with their GPs, and underestimate the risks of both prescribed and herbal medication. The new GP contract puts a clear responsibility upon GPs to regularly review patients and to ensure that treatments are based on sound evidence. This has led to more prescriptions being issued; adverse drug reactions are associated with both age and the total number of types of drug being taken. There are effective ways of educating patients about their medication. The authors suggest that this should include an enquiry about herbal medicine use, particularly with those at high risk, such as older people and those taking warfarin. Where control of INR is poor, it is expected that GPs would explore whether herbal medications or other OTC preparations that might affect the INR are being taken.

Implications for clinical practice and future research

The authors argue that the effect of prescription changes warrants further exploration, as the prevalence of interaction is around the same level as for herbal and complementary medicine self-medication. There may well be certain clinical scenarios when such discussion will become mandatory in the future, such as certain diseases, for example diabetes, malignancy, and certain genetic variants, or when INR control is difficult to achieve. Further research would be warranted into the potential for interactions between any oral therapy and warfarin in terms of adverse effects, advice to patients, and whether increased INR monitoring is needed when drug changes are made.

Funding body

The Rufford Maurice Laing Foundation (reference 10522)

Ethics committee

Somerset REC (04/Q2202/47)

Competing interests

The authors have stated that there are none

Acknowledgements

We would like to thank all practices who distributed questionnaire packs to their patients, and all patients who returned study documentation allowing access to their notes.

Discuss this article

Contribute and read comments about this article on the Discussion Forum: http://www.rcp.org.uk/bjgp-discuss

REFERENCES

9. Glasheen JJ, Fuigit JV, Prochazka MD. The risk of over-anticoagulation with anticoagulants in outpatients on warfarin regimes. J G In